In prostate cancer, the frequency of TSC1 and TBC1D7 mutation or deep deletion is low (≤0.8% incidence, Tables S1–S3), whereas TSC2 mutation and deep deletion are more frequent (1–1.8% and up to 4.2% of cases respectively, Tables S1–S3). This evidence concerns the gene TSC2 and prostate carcinoma.